BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8479078)

  • 21. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
    Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
    Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
    Tauro S; Hepburn MD; Bowen DT; Pippard MJ
    Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
    Takeyama H; Kajiguchi T; Miyata Y; Saito M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):873-8. PubMed ID: 10897214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
    Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
    Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia.
    Tennant GB; Walsh V; Truran LN; Edwards P; Mills KI; Burnett AK
    Br J Haematol; 2000 Dec; 111(3):853-62. PubMed ID: 11122147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of hematopoietic growth factors on extensive apoptosis of myelodysplastic hematopoietic cells and its clinical significance].
    Cao Z; Li R; Li Q
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jan; 19(1):27-30. PubMed ID: 10921099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes.
    Ferrara F; Leoni F; Pinto A; Mirto S; Morra E; Zagonel V; Mele G; Ciolli S; Magrin S; Montillo M
    Cancer; 1999 Nov; 86(10):2006-13. PubMed ID: 10570425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with growth factors in myelodysplastic syndromes.
    Geissler RG; Schulte P; Ganser A
    Pathol Biol (Paris); 1997 Oct; 45(8):656-67. PubMed ID: 9569932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells.
    Rigolin GM; Porta MD; Ciccone M; Bugli AM; Bragotti LZ; Mauro E; Fraulini C; Rossi AR; Bardi A; Cuneo A; Castoldi G
    Br J Haematol; 2004 Aug; 126(4):501-7. PubMed ID: 15287942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnosis and therapy strategy in myelodysplastic syndromes].
    Gattermann N; Aul C
    Praxis (Bern 1994); 1996 Jan; 85(3):39-44. PubMed ID: 8578048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The implications of the biological indices examination of bone marrow cells in myelodysplastic syndromes].
    Zhang F; Hao Y; Pang W
    Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):528-32. PubMed ID: 11769678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.
    Ribeiro E; Matarraz Sudón S; de Santiago M; Lima CS; Metze K; Giralt M; Saad ST; de Matos AO; Lorand-Metze I
    Leuk Res; 2006 Jan; 30(1):9-16. PubMed ID: 16005514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelodysplastic syndromes: a review for nurses.
    Cain J; Hood-Barnes J; Spangler J
    Oncol Nurs Forum; 1991; 18(1):113-7. PubMed ID: 2003103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.